berotek has been researched along with Diseases, Metabolic in 1 studies
Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.
fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tzvetkov, MV | 1 |
| Matthaei, J | 1 |
| Pojar, S | 1 |
| Faltraco, F | 1 |
| Vogler, S | 1 |
| Prukop, T | 1 |
| Seitz, T | 1 |
| Brockmöller, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Genetic Polymorphisms in the Organic Cation Transporter OCT1 on Cellular Uptake and Metabolism of Antidepressants and Other Organic Cationic Drugs[NCT02054299] | Phase 1 | 48 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for berotek and Diseases, Metabolic
| Article | Year |
|---|---|
Increased Systemic Exposure and Stronger Cardiovascular and Metabolic Adverse Reactions to Fenoterol in Individuals with Heritable OCT1 Deficiency.
Topics: Alleles; Biological Transport; Blood Glucose; Cardiovascular System; Drug-Related Side Effects and A | 2018 |